世界の5-ヒドロキシトリプタミン受容体アゴニスト市場インサイト及び予測(ドラセトロン、グラニセトロン、オンダンセトロン、トロピセトロン、その他)

◆英語タイトル:Global 5-Hydroxytryptamine Receptor Agonist Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX09211)◆商品コード:QY22JLX09211
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:112
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、5-ヒドロキシトリプタミン受容体アゴニストのグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年に5-ヒドロキシトリプタミン受容体アゴニストの世界市場のxxx%を占める「ドラセトロン」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院薬局」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
5-ヒドロキシトリプタミン受容体アゴニストの中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパの5-ヒドロキシトリプタミン受容体アゴニスト市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

5-ヒドロキシトリプタミン受容体アゴニストのグローバル主要企業には、Heron Therapeutics、Kyowa Kirin、Bionpharma、Fresenius Kabi、Aurobindo Pharma、Mylan NV、Sun Pharmaceutical Industries、Akron Incorporated、Hikma Pharmaceuticals、Dr. Reddy's Laboratories、Cipla、Novartis、Glenmark Pharmaceuticals、Apotex、Novo Nordisk、Otsuka America Pharmaceutical、Bristol-Myers Squibb Company、Teva Pharmaceutical Industries、WOCKHARDTなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

5-ヒドロキシトリプタミン受容体アゴニスト市場は、種類と用途によって区分されます。世界の5-ヒドロキシトリプタミン受容体アゴニスト市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
ドラセトロン、グラニセトロン、オンダンセトロン、トロピセトロン、その他

【用途別セグメント】
病院薬局、小売薬局、オンライン薬局

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 5-ヒドロキシトリプタミン受容体アゴニスト製品概要
- 種類別市場(ドラセトロン、グラニセトロン、オンダンセトロン、トロピセトロン、その他)
- 用途別市場(病院薬局、小売薬局、オンライン薬局)
- 調査の目的
・エグゼクティブサマリー
- 世界の5-ヒドロキシトリプタミン受容体アゴニスト販売量予測2017-2028
- 世界の5-ヒドロキシトリプタミン受容体アゴニスト売上予測2017-2028
- 5-ヒドロキシトリプタミン受容体アゴニストの地域別販売量
- 5-ヒドロキシトリプタミン受容体アゴニストの地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別5-ヒドロキシトリプタミン受容体アゴニスト販売量
- 主要メーカー別5-ヒドロキシトリプタミン受容体アゴニスト売上
- 主要メーカー別5-ヒドロキシトリプタミン受容体アゴニスト価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(ドラセトロン、グラニセトロン、オンダンセトロン、トロピセトロン、その他)
- 5-ヒドロキシトリプタミン受容体アゴニストの種類別販売量
- 5-ヒドロキシトリプタミン受容体アゴニストの種類別売上
- 5-ヒドロキシトリプタミン受容体アゴニストの種類別価格
・用途別市場規模(病院薬局、小売薬局、オンライン薬局)
- 5-ヒドロキシトリプタミン受容体アゴニストの用途別販売量
- 5-ヒドロキシトリプタミン受容体アゴニストの用途別売上
- 5-ヒドロキシトリプタミン受容体アゴニストの用途別価格
・北米市場
- 北米の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(種類別、用途別)
- 主要国別の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの5-ヒドロキシトリプタミン受容体アゴニスト市場規模(種類別、用途別)
- 主要国別の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(種類別、用途別)
- 主要国別の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(種類別、用途別)
- 主要国別の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの5-ヒドロキシトリプタミン受容体アゴニスト市場規模(種類別、用途別)
- 主要国別の5-ヒドロキシトリプタミン受容体アゴニスト市場規模(トルコ、サウジアラビア)
・企業情報
Heron Therapeutics、Kyowa Kirin、Bionpharma、Fresenius Kabi、Aurobindo Pharma、Mylan NV、Sun Pharmaceutical Industries、Akron Incorporated、Hikma Pharmaceuticals、Dr. Reddy's Laboratories、Cipla、Novartis、Glenmark Pharmaceuticals、Apotex、Novo Nordisk、Otsuka America Pharmaceutical、Bristol-Myers Squibb Company、Teva Pharmaceutical Industries、WOCKHARDT
・産業チェーン及び販売チャネル分析
- 5-ヒドロキシトリプタミン受容体アゴニストの産業チェーン分析
- 5-ヒドロキシトリプタミン受容体アゴニストの原材料
- 5-ヒドロキシトリプタミン受容体アゴニストの生産プロセス
- 5-ヒドロキシトリプタミン受容体アゴニストの販売及びマーケティング
- 5-ヒドロキシトリプタミン受容体アゴニストの主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 5-ヒドロキシトリプタミン受容体アゴニストの産業動向
- 5-ヒドロキシトリプタミン受容体アゴニストのマーケットドライバー
- 5-ヒドロキシトリプタミン受容体アゴニストの課題
- 5-ヒドロキシトリプタミン受容体アゴニストの阻害要因
・主な調査結果

Market Analysis and Insights: Global 5-Hydroxytryptamine Receptor Agonist Market
Due to the COVID-19 pandemic, the global 5-Hydroxytryptamine Receptor Agonist market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Dolasetron accounting for % of the 5-Hydroxytryptamine Receptor Agonist global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacy segment is altered to an % CAGR throughout this forecast period.
China 5-Hydroxytryptamine Receptor Agonist market size is valued at US$ million in 2021, while the US and Europe 5-Hydroxytryptamine Receptor Agonist are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe 5-Hydroxytryptamine Receptor Agonist landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of 5-Hydroxytryptamine Receptor Agonist include Heron Therapeutics, Kyowa Kirin, Bionpharma, Fresenius Kabi, Aurobindo Pharma, Mylan NV, Sun Pharmaceutical Industries, Akron Incorporated and Hikma Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global 5-Hydroxytryptamine Receptor Agonist Scope and Segment
5-Hydroxytryptamine Receptor Agonist market is segmented by Type and by Application. Players, stakeholders, and other participants in the global 5-Hydroxytryptamine Receptor Agonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Dolasetron
Granisetron
Ondansetron
Tropisetron
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By Company
Heron Therapeutics
Kyowa Kirin
Bionpharma
Fresenius Kabi
Aurobindo Pharma
Mylan NV
Sun Pharmaceutical Industries
Akron Incorporated
Hikma Pharmaceuticals
Dr. Reddy’s Laboratories
Cipla
Novartis
Glenmark Pharmaceuticals
Apotex
Novo Nordisk
Otsuka America Pharmaceutical
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries
WOCKHARDT
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 5-Hydroxytryptamine Receptor Agonist Product Introduction
1.2 Market by Type
1.2.1 Global 5-Hydroxytryptamine Receptor Agonist Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Dolasetron
1.2.3 Granisetron
1.2.4 Ondansetron
1.2.5 Tropisetron
1.2.6 Others
1.3 Market by Application
1.3.1 Global 5-Hydroxytryptamine Receptor Agonist Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global 5-Hydroxytryptamine Receptor Agonist Sales Estimates and Forecasts 2017-2028
2.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue Estimates and Forecasts 2017-2028
2.3 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global 5-Hydroxytryptamine Receptor Agonist Sales by Region
2.4.1 Global 5-Hydroxytryptamine Receptor Agonist Sales by Region (2017-2022)
2.4.2 Global Sales 5-Hydroxytryptamine Receptor Agonist by Region (2023-2028)
2.5 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Region
2.5.1 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Region (2017-2022)
2.5.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global 5-Hydroxytryptamine Receptor Agonist Sales by Manufacturers
3.1.1 Global Top 5-Hydroxytryptamine Receptor Agonist Manufacturers by Sales (2017-2022)
3.1.2 Global 5-Hydroxytryptamine Receptor Agonist Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of 5-Hydroxytryptamine Receptor Agonist in 2021
3.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Manufacturers
3.2.1 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Manufacturers (2017-2022)
3.2.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by 5-Hydroxytryptamine Receptor Agonist Revenue in 2021
3.3 Global 5-Hydroxytryptamine Receptor Agonist Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global 5-Hydroxytryptamine Receptor Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global 5-Hydroxytryptamine Receptor Agonist Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global 5-Hydroxytryptamine Receptor Agonist Sales by Type
4.1.1 Global 5-Hydroxytryptamine Receptor Agonist Historical Sales by Type (2017-2022)
4.1.2 Global 5-Hydroxytryptamine Receptor Agonist Forecasted Sales by Type (2023-2028)
4.1.3 Global 5-Hydroxytryptamine Receptor Agonist Sales Market Share by Type (2017-2028)
4.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Type
4.2.1 Global 5-Hydroxytryptamine Receptor Agonist Historical Revenue by Type (2017-2022)
4.2.2 Global 5-Hydroxytryptamine Receptor Agonist Forecasted Revenue by Type (2023-2028)
4.2.3 Global 5-Hydroxytryptamine Receptor Agonist Revenue Market Share by Type (2017-2028)
4.3 Global 5-Hydroxytryptamine Receptor Agonist Price by Type
4.3.1 Global 5-Hydroxytryptamine Receptor Agonist Price by Type (2017-2022)
4.3.2 Global 5-Hydroxytryptamine Receptor Agonist Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global 5-Hydroxytryptamine Receptor Agonist Sales by Application
5.1.1 Global 5-Hydroxytryptamine Receptor Agonist Historical Sales by Application (2017-2022)
5.1.2 Global 5-Hydroxytryptamine Receptor Agonist Forecasted Sales by Application (2023-2028)
5.1.3 Global 5-Hydroxytryptamine Receptor Agonist Sales Market Share by Application (2017-2028)
5.2 Global 5-Hydroxytryptamine Receptor Agonist Revenue by Application
5.2.1 Global 5-Hydroxytryptamine Receptor Agonist Historical Revenue by Application (2017-2022)
5.2.2 Global 5-Hydroxytryptamine Receptor Agonist Forecasted Revenue by Application (2023-2028)
5.2.3 Global 5-Hydroxytryptamine Receptor Agonist Revenue Market Share by Application (2017-2028)
5.3 Global 5-Hydroxytryptamine Receptor Agonist Price by Application
5.3.1 Global 5-Hydroxytryptamine Receptor Agonist Price by Application (2017-2022)
5.3.2 Global 5-Hydroxytryptamine Receptor Agonist Price Forecast by Application (2023-2028)
6 North America
6.1 North America 5-Hydroxytryptamine Receptor Agonist Market Size by Type
6.1.1 North America 5-Hydroxytryptamine Receptor Agonist Sales by Type (2017-2028)
6.1.2 North America 5-Hydroxytryptamine Receptor Agonist Revenue by Type (2017-2028)
6.2 North America 5-Hydroxytryptamine Receptor Agonist Market Size by Application
6.2.1 North America 5-Hydroxytryptamine Receptor Agonist Sales by Application (2017-2028)
6.2.2 North America 5-Hydroxytryptamine Receptor Agonist Revenue by Application (2017-2028)
6.3 North America 5-Hydroxytryptamine Receptor Agonist Market Size by Country
6.3.1 North America 5-Hydroxytryptamine Receptor Agonist Sales by Country (2017-2028)
6.3.2 North America 5-Hydroxytryptamine Receptor Agonist Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe 5-Hydroxytryptamine Receptor Agonist Market Size by Type
7.1.1 Europe 5-Hydroxytryptamine Receptor Agonist Sales by Type (2017-2028)
7.1.2 Europe 5-Hydroxytryptamine Receptor Agonist Revenue by Type (2017-2028)
7.2 Europe 5-Hydroxytryptamine Receptor Agonist Market Size by Application
7.2.1 Europe 5-Hydroxytryptamine Receptor Agonist Sales by Application (2017-2028)
7.2.2 Europe 5-Hydroxytryptamine Receptor Agonist Revenue by Application (2017-2028)
7.3 Europe 5-Hydroxytryptamine Receptor Agonist Market Size by Country
7.3.1 Europe 5-Hydroxytryptamine Receptor Agonist Sales by Country (2017-2028)
7.3.2 Europe 5-Hydroxytryptamine Receptor Agonist Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Market Size by Type
8.1.1 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Sales by Type (2017-2028)
8.1.2 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Revenue by Type (2017-2028)
8.2 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Market Size by Application
8.2.1 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Sales by Application (2017-2028)
8.2.2 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Revenue by Application (2017-2028)
8.3 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Market Size by Region
8.3.1 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Sales by Region (2017-2028)
8.3.2 Asia Pacific 5-Hydroxytryptamine Receptor Agonist Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America 5-Hydroxytryptamine Receptor Agonist Market Size by Type
9.1.1 Latin America 5-Hydroxytryptamine Receptor Agonist Sales by Type (2017-2028)
9.1.2 Latin America 5-Hydroxytryptamine Receptor Agonist Revenue by Type (2017-2028)
9.2 Latin America 5-Hydroxytryptamine Receptor Agonist Market Size by Application
9.2.1 Latin America 5-Hydroxytryptamine Receptor Agonist Sales by Application (2017-2028)
9.2.2 Latin America 5-Hydroxytryptamine Receptor Agonist Revenue by Application (2017-2028)
9.3 Latin America 5-Hydroxytryptamine Receptor Agonist Market Size by Country
9.3.1 Latin America 5-Hydroxytryptamine Receptor Agonist Sales by Country (2017-2028)
9.3.2 Latin America 5-Hydroxytryptamine Receptor Agonist Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Market Size by Type
10.1.1 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Sales by Type (2017-2028)
10.1.2 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Revenue by Type (2017-2028)
10.2 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Market Size by Application
10.2.1 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Sales by Application (2017-2028)
10.2.2 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Revenue by Application (2017-2028)
10.3 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Market Size by Country
10.3.1 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Sales by Country (2017-2028)
10.3.2 Middle East and Africa 5-Hydroxytryptamine Receptor Agonist Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Heron Therapeutics
11.1.1 Heron Therapeutics Corporation Information
11.1.2 Heron Therapeutics Overview
11.1.3 Heron Therapeutics 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Heron Therapeutics 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Heron Therapeutics Recent Developments
11.2 Kyowa Kirin
11.2.1 Kyowa Kirin Corporation Information
11.2.2 Kyowa Kirin Overview
11.2.3 Kyowa Kirin 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Kyowa Kirin 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Kyowa Kirin Recent Developments
11.3 Bionpharma
11.3.1 Bionpharma Corporation Information
11.3.2 Bionpharma Overview
11.3.3 Bionpharma 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Bionpharma 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Bionpharma Recent Developments
11.4 Fresenius Kabi
11.4.1 Fresenius Kabi Corporation Information
11.4.2 Fresenius Kabi Overview
11.4.3 Fresenius Kabi 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Fresenius Kabi 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Fresenius Kabi Recent Developments
11.5 Aurobindo Pharma
11.5.1 Aurobindo Pharma Corporation Information
11.5.2 Aurobindo Pharma Overview
11.5.3 Aurobindo Pharma 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Aurobindo Pharma 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Aurobindo Pharma Recent Developments
11.6 Mylan NV
11.6.1 Mylan NV Corporation Information
11.6.2 Mylan NV Overview
11.6.3 Mylan NV 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Mylan NV 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Mylan NV Recent Developments
11.7 Sun Pharmaceutical Industries
11.7.1 Sun Pharmaceutical Industries Corporation Information
11.7.2 Sun Pharmaceutical Industries Overview
11.7.3 Sun Pharmaceutical Industries 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Sun Pharmaceutical Industries 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Sun Pharmaceutical Industries Recent Developments
11.8 Akron Incorporated
11.8.1 Akron Incorporated Corporation Information
11.8.2 Akron Incorporated Overview
11.8.3 Akron Incorporated 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Akron Incorporated 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Akron Incorporated Recent Developments
11.9 Hikma Pharmaceuticals
11.9.1 Hikma Pharmaceuticals Corporation Information
11.9.2 Hikma Pharmaceuticals Overview
11.9.3 Hikma Pharmaceuticals 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Hikma Pharmaceuticals 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Hikma Pharmaceuticals Recent Developments
11.10 Dr. Reddy’s Laboratories
11.10.1 Dr. Reddy’s Laboratories Corporation Information
11.10.2 Dr. Reddy’s Laboratories Overview
11.10.3 Dr. Reddy’s Laboratories 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Dr. Reddy’s Laboratories 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Dr. Reddy’s Laboratories Recent Developments
11.11 Cipla
11.11.1 Cipla Corporation Information
11.11.2 Cipla Overview
11.11.3 Cipla 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Cipla 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Cipla Recent Developments
11.12 Novartis
11.12.1 Novartis Corporation Information
11.12.2 Novartis Overview
11.12.3 Novartis 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Novartis 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Novartis Recent Developments
11.13 Glenmark Pharmaceuticals
11.13.1 Glenmark Pharmaceuticals Corporation Information
11.13.2 Glenmark Pharmaceuticals Overview
11.13.3 Glenmark Pharmaceuticals 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Glenmark Pharmaceuticals 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Glenmark Pharmaceuticals Recent Developments
11.14 Apotex
11.14.1 Apotex Corporation Information
11.14.2 Apotex Overview
11.14.3 Apotex 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Apotex 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Apotex Recent Developments
11.15 Novo Nordisk
11.15.1 Novo Nordisk Corporation Information
11.15.2 Novo Nordisk Overview
11.15.3 Novo Nordisk 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Novo Nordisk 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Novo Nordisk Recent Developments
11.16 Otsuka America Pharmaceutical
11.16.1 Otsuka America Pharmaceutical Corporation Information
11.16.2 Otsuka America Pharmaceutical Overview
11.16.3 Otsuka America Pharmaceutical 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Otsuka America Pharmaceutical 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Otsuka America Pharmaceutical Recent Developments
11.17 Bristol-Myers Squibb Company
11.17.1 Bristol-Myers Squibb Company Corporation Information
11.17.2 Bristol-Myers Squibb Company Overview
11.17.3 Bristol-Myers Squibb Company 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Bristol-Myers Squibb Company 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Bristol-Myers Squibb Company Recent Developments
11.18 Teva Pharmaceutical Industries
11.18.1 Teva Pharmaceutical Industries Corporation Information
11.18.2 Teva Pharmaceutical Industries Overview
11.18.3 Teva Pharmaceutical Industries 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Teva Pharmaceutical Industries 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Teva Pharmaceutical Industries Recent Developments
11.19 WOCKHARDT
11.19.1 WOCKHARDT Corporation Information
11.19.2 WOCKHARDT Overview
11.19.3 WOCKHARDT 5-Hydroxytryptamine Receptor Agonist Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 WOCKHARDT 5-Hydroxytryptamine Receptor Agonist Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 WOCKHARDT Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 5-Hydroxytryptamine Receptor Agonist Industry Chain Analysis
12.2 5-Hydroxytryptamine Receptor Agonist Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 5-Hydroxytryptamine Receptor Agonist Production Mode & Process
12.4 5-Hydroxytryptamine Receptor Agonist Sales and Marketing
12.4.1 5-Hydroxytryptamine Receptor Agonist Sales Channels
12.4.2 5-Hydroxytryptamine Receptor Agonist Distributors
12.5 5-Hydroxytryptamine Receptor Agonist Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 5-Hydroxytryptamine Receptor Agonist Industry Trends
13.2 5-Hydroxytryptamine Receptor Agonist Market Drivers
13.3 5-Hydroxytryptamine Receptor Agonist Market Challenges
13.4 5-Hydroxytryptamine Receptor Agonist Market Restraints
14 Key Findings in The Global 5-Hydroxytryptamine Receptor Agonist Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の5-ヒドロキシトリプタミン受容体アゴニスト市場インサイト及び予測(ドラセトロン、グラニセトロン、オンダンセトロン、トロピセトロン、その他)(Global 5-Hydroxytryptamine Receptor Agonist Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。